Who Buys Carmustine from India — 135 Importers Behind a $22.5M Market
India's carmustine import market is served by 135 active buyers who collectively imported $22.5M across 340 shipments. TILLOMED LABORATORIES LTD (UNITED KINGDOM) leads with a 56.9% market share, followed by STERIMAX INC and TILLOMED MALTA LTD. The top 5 buyers together control 80.4% of total import value, reflecting a concentrated buyer landscape.
Top Carmustine Importers — Ranked by Import Value
TILLOMED LABORATORIES LTD (UNITED KINGDOM) is the leading carmustine importer from India, holding a 56.9% share of the $22.5M market across 340 shipments from 135 buyers. The top 5 buyers — TILLOMED LABORATORIES LTD (UNITED KINGDOM), STERIMAX INC (CANADA), TILLOMED MALTA LTD (MALTA), AVET PHARMACEUTICALS INC. (UNITED STATES), JSC VILNIAUS TRANZITAS (LITHUANIA) — collectively control 80.4% of total import value.
Top Carmustine Buyers & Importers
Ranked by import value · 135 active buyers · Indian Customs (DGFT) data
| # | Buyer & Formulations | Value | Suppliers | Share |
|---|---|---|---|---|
| 1 | TILLOMED LABORATORIES LTDUNITED KINGDOM CARMUSTINE FOR INJECTION USP 100MG/VIAL.CARMUSTINE FOR INJECTION USP 100MG/VIALMEDICINES BICNU 100MG INJ.WT DILUENT | $12.8M | 5 | 56.9% |
| 2 | STERIMAX INCCANADA CARMUSTINE FOR INJECTION USP 100 MGCOMBI PACK BICNU(CARMUSTINE FOR INJ 100MCARMUSTINE FOR INJECTION USP 100 MG 900NOS550 | $1.9M | 5 | 8.3% |
| 3 | TILLOMED MALTA LTDMALTA CARMUSTINE FOR INJECTION USP 100MG/VIAL.CARMUSTINE FOR INJECTION USP 100MG/VIALMEDICINES BICNU 100MG INJ.WT DILUENT | $1.8M | 5 | 8.2% |
| 4 | AVET PHARMACEUTICALS INC.UNITED STATES -CARMUSTINE FOR INJECTION USCARMUSTINE FOR INJ USP 100MG/VIAL AP USVLSCARMUSTINE FOR INJECTION USP 100 MG/VIAL | $1.1M | 5 | 4.9% |
| 5 | JSC VILNIAUS TRANZITASLITHUANIA PHARMA:CARMUSTINE 100MG INJECTION WT DILCARMUSTINE PH .EUR. B | $462.6K | 5 | 2.1% |
| 6 | EVERSANA LIFE SCIENCES SERVICES,LLCUNITED STATES | $461.6K | 5 | 2.1% |
| 7 | TILLOMED LABORATORIES LIMITEDUNITED KINGDOM CARMUSTINE FOR INJECTION USP 100MG/VIAL.CARMUSTINE FOR INJECTION USP 100MG/VIALMEDICINES BICNU 100MG INJ.WT DILUENT | $267.4K | 5 | 1.2% |
| 8 | HIND WING CO.LTD.HONG KONG PHARMA : BICNU 100MG INJECTION - 1 VIALPHARMACEUTICAL PRODUCTS:BICNU 100 MG INJ1 VIALNOSPHARMACEUTICALS PRODUCTS: BICNU 100 MG INJ 1 VIAL | $257.2K | 5 | 1.1% |
| 9 | TILLOMED ITALIA SRL .ITALY CARMUSTINE FOR INJECTION USP 100MG/VIAL.CARMUSTINE FOR INJECTION USP 100MG/VIALMEDICINES BICNU 100MG INJ.WT DILUENT | $208.8K | 5 | 0.9% |
| 10 | ARABIAN HEALTH CARE SUPPLY COSAUDI ARABIA | $173.7K | 5 | 0.8% |
| 11 | BROCACEF NL:HUB BROCACEF HEALTHCARNETHERLANDS PHARMA DRUGS & MEDI: CARMUSTINE 100MG/V,PHARMA DRUGS & MEDI CARMUSTINE 100MG/V,1 | $137.0K | 5 | 0.6% |
| 12 | BROCACEF NL : DUTCHNETHERLANDS PHARMA DRUGS & MEDI: CARMUSTINE 100MG/V,PHARMA DRUGS & MEDI CARMUSTINE 100MG/V,1 | $123.3K | 5 | 0.5% |
| 13 | DRAGON PHARMACEUTICALS CO LTD.,TAIWAN CARMUSTINE FOR INJECTION USP 100 MGCARMUSTINE FOR INJECTION USP 100 MG VLSCARMUSTINE FOR INJECTION USP 100 MG CARMUTHER 100 | $98.9K | 5 | 0.4% |
| 14 | DRAGON PHARMACEUTICAL CO LIMITEDTAIWAN CARMUSTINE FOR INJECTION USP 100 MGCARMUSTINE FOR INJECTION USP 100 MG VLSCARMUSTINE FOR INJECTION USP 100 MG CARMUTHER 100 | $98.9K | 5 | 0.4% |
Related Analysis
Market Analysis: Top Importing Countries & Importers
Comprehensive geographic market intelligence dashboard
Which companies are buying Carmustine — and from which countries?
Flow of Carmustine exports from India: each country's share and the named importers behind the numbers
Carmustine — Buyer Countries to Key Importers
Trade flow: top importing countries → named buyer companies
Market Analysis: Top Importing Countries & Their Importers
1United Kingdom
United Kingdom emerges as the first largest importing country, achieving a total trade value of $13.1M through 18 shipments. This represents a market share of 58.1% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: United Kingdom has a diverse importer base, with their top importers including:
• TILLOMED LABORATORIES LTD - $12.8M (97.9% of country's total business)
• TILLOMED LABORATORIES LIMITED - $267.4K (2.0% of country's total business)
Key Insight: United Kingdom demonstrates strong market positioning with an average shipment value of $726.4K, indicating premium pricing strategy compared to the market average of $66.2K.
United Kingdom is a key market for Carmustine imports, representing 58.1% of total trade value.
2Canada
Canada emerges as the second largest importing country, achieving a total trade value of $2.8M through 7 shipments. This represents a market share of 12.6% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Canada has a diverse importer base, with their top importers including:
• STERIMAX INC - $1.9M (66.3% of country's total business)
Key Insight: Canada demonstrates strong market positioning with an average shipment value of $403.9K, indicating premium pricing strategy compared to the market average of $66.2K.
Canada is a key market for Carmustine imports, representing 12.6% of total trade value.
3Malta
Malta emerges as the third largest importing country, achieving a total trade value of $2.0M through 23 shipments. This represents a market share of 8.7% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Malta has a diverse importer base, with their top importers including:
• TILLOMED MALTA LTD - $1.8M (93.7% of country's total business)
Key Insight: Malta demonstrates strong market positioning with an average shipment value of $85.2K, indicating premium pricing strategy compared to the market average of $66.2K.
Malta is a key market for Carmustine imports, representing 8.7% of total trade value.
4United States
United States emerges as the fourth largest importing country, achieving a total trade value of $1.8M through 5 shipments. This represents a market share of 7.9% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: United States has a diverse importer base, with their top importers including:
• AVET PHARMACEUTICALS INC. - $1.1M (61.5% of country's total business)
• EVERSANA LIFE SCIENCES SERVICES,LLC - $461.6K (25.8% of country's total business)
Key Insight: United States demonstrates strong market positioning with an average shipment value of $357.3K, indicating premium pricing strategy compared to the market average of $66.2K.
United States is a key market for Carmustine imports, representing 7.9% of total trade value.
5Lithuania
Lithuania emerges as the fifth largest importing country, achieving a total trade value of $462.6K through 3 shipments. This represents a market share of 2.1% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Lithuania has a diverse importer base, with their top importers including:
• JSC VILNIAUS TRANZITAS - $462.6K (100.0% of country's total business)
Key Insight: Lithuania demonstrates strong market positioning with an average shipment value of $154.2K, indicating premium pricing strategy compared to the market average of $66.2K.
Lithuania is a key market for Carmustine imports, representing 2.1% of total trade value.
Buyer Segment Analysis
TransData Nexus Carmustine buyer market intelligence
1Buyer Segment Analysis
The importation of Carmustine from India involves various buyer segments, each with distinct purchasing behaviors:
- Distributors: Entities like TILLOMED LABORATORIES LTD (United Kingdom) and STERIMAX INC (Canada) function as intermediaries, procuring Carmustine in bulk to supply to healthcare providers. Their purchasing patterns are characterized by large-volume orders and a focus on maintaining consistent supply chains to meet market demand.
- Hospital Groups: Organizations such as JSC VILNIAUS TRANZITAS (Lithuania) and ARABIAN HEALTH CARE SUPPLY CO (Saudi Arabia) represent hospital networks that import Carmustine directly for patient treatment. Their procurement is driven by patient needs, leading to regular, moderate-sized orders aligned with treatment schedules.
- Re-exporters: Companies like TILLOMED MALTA LTD (Malta) and TILLOMED ITALIA SRL (Italy) may act as re-exporters, importing Carmustine for redistribution to other markets. This segment's buying behavior includes purchasing in bulk and managing logistics to serve multiple regions.
- Contract Manufacturers: Entities such as AVET PHARMACEUTICALS INC. (United States) and EVERSANA LIFE SCIENCES SERVICES, LLC (United States) may import Carmustine as raw material for further processing or formulation. Their procurement patterns involve bulk purchases aligned with production schedules and regulatory compliance requirements.
Understanding these segments is crucial for tailoring supply strategies and ensuring efficient distribution of Carmustine across diverse markets.
Country-Specific Import Regulations
TransData Nexus Carmustine buyer market intelligence
1Country-Specific Import Regulations
Import regulations for Carmustine vary across the top importing countries:
- United Kingdom:
- Regulatory Authority: Medicines and Healthcare products Regulatory Agency (MHRA).
- Import Registration Process: Importers must hold a Wholesale Dealer's Licence (WDA(H)) and ensure that Carmustine is registered under the UK Marketing Authorisation.
- Estimated Timeline for Registration: Approximately 6-12 months, depending on the completeness of the application and MHRA's review process.
- Import Tariff/Duty for HS 30049049: Pharmaceutical products under this HS code are typically subject to a 0% import duty in the UK.
- Canada:
- Regulatory Authority: Health Canada.
- Import Registration Process: Importers must obtain a Drug Establishment Licence (DEL) and ensure Carmustine is listed on the Notice of Compliance (NOC) database.
- Estimated Timeline for Registration: Approximately 12-18 months, contingent on the submission's complexity and Health Canada's evaluation.
- Import Tariff/Duty for HS 30049049: Pharmaceuticals under this code are generally duty-free in Canada.
- Malta:
- Regulatory Authority: Malta Medicines Authority (MMA).
- Import Registration Process: Importers need a Wholesale Dealer Licence and must ensure Carmustine is authorized for the Maltese market.
- Estimated Timeline for Registration: Approximately 6-9 months, subject to MMA's assessment procedures.
- Import Tariff/Duty for HS 30049049: As an EU member, Malta applies a 0% import duty on pharmaceutical products under this HS code.
- United States:
- Regulatory Authority: U.S. Food and Drug Administration (FDA).
- Import Registration Process: Importers must register with the FDA, and Carmustine must have an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA).
- Estimated Timeline for Registration: Approximately 12-24 months, depending on the application type and FDA's review process.
- Import Tariff/Duty for HS 30049049: Pharmaceuticals under this code are typically duty-free in the U.S.
- Lithuania:
- Regulatory Authority: State Medicines Control Agency (SMCA).
- Import Registration Process: Importers must obtain a Wholesale Distribution Authorisation and ensure Carmustine is registered in Lithuania.
- Estimated Timeline for Registration: Approximately 6-12 months, based on SMCA's evaluation process.
- Import Tariff/Duty for HS 30049049: As an EU member, Lithuania applies a 0% import duty on pharmaceutical products under this HS code.
Compliance with these regulations is essential for market entry and sustained distribution of Carmustine in these countries.
Demand Drivers & Market Opportunity
TransData Nexus Carmustine buyer market intelligence
1Demand Drivers & Market Opportunity
The demand for Carmustine in importing countries is influenced by several factors:
- Disease Prevalence: Carmustine is primarily used in the treatment of certain cancers, including brain tumors and Hodgkin's lymphoma. The global incidence of these cancers has been rising, necessitating increased availability of effective treatments.
- Government Healthcare Programs: Many countries have national cancer control programs that prioritize access to essential oncology drugs. For instance, the WHO's inclusion of new cancer treatments in its Essential Medicines List in 2025 underscores the global commitment to improving cancer care.
- Universal Health Coverage Expansion: Efforts to achieve universal health coverage have led to increased procurement of essential medicines, including Carmustine, to ensure comprehensive cancer treatment is accessible to all patients.
- WHO Essential Medicines List Procurement: The inclusion of Carmustine in the WHO Essential Medicines List facilitates its procurement by member countries, aligning with international standards for essential cancer treatments.
- Tender-Based Purchasing: Many healthcare systems utilize tender processes to procure pharmaceuticals, ensuring cost-effectiveness and consistent supply. The presence of 135 buyers across 54 countries indicates a competitive market where tendering is a common practice.
These factors collectively drive the demand for Carmustine, presenting significant market opportunities for suppliers to meet the growing needs of global healthcare systems.
Common Questions — Carmustine Buyers & Importers
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
QWho is the largest carmustine buyer importing from India?
Based on import volume and value, TILLOMED LABORATORIES LTD (UNITED KINGDOM) leads with $12.8M in imports and a 56.9% market share — the highest of any single carmustine importer. STERIMAX INC (CANADA) and TILLOMED MALTA LTD (MALTA) are the next largest buyers.
QHow many companies buy carmustine from India?
There are 135 active carmustine buyers importing from India, with a combined market of $22.5M across 340 shipments to 54 countries. The top 5 buyers hold 80.4% of total import value, while the remaining 130 buyers handle the other 19.6%.
QWhich countries import the most carmustine from India?
The top importing countries for carmustine from India are United Kingdom (58.1%), Canada (12.6%), Malta (8.7%), United States (7.9%), Lithuania (2.1%). These markets represent the largest demand centres for Indian pharmaceutical exports of carmustine, with buyers ranging from government procurement agencies to private pharmaceutical distributors.
QWhat is the average import order value for carmustine from India?
The average import transaction value for carmustine from India is $66.2K, with an average unit price of $116.59 per unit. Order sizes vary significantly based on buyer type — government tenders tend to be larger while private distributors place more frequent smaller orders.
Buyer Segment Analysis
TransData Nexus Carmustine buyer market intelligence
1Buyer Segment Analysis
The importation of Carmustine from India involves various buyer segments, each with distinct purchasing behaviors:
- Distributors: Entities like TILLOMED LABORATORIES LTD (United Kingdom) and STERIMAX INC (Canada) function as intermediaries, procuring Carmustine in bulk to supply to healthcare providers. Their purchasing patterns are characterized by large-volume orders and a focus on maintaining consistent supply chains to meet market demand.
- Hospital Groups: Organizations such as JSC VILNIAUS TRANZITAS (Lithuania) and ARABIAN HEALTH CARE SUPPLY CO (Saudi Arabia) represent hospital networks that import Carmustine directly for patient treatment. Their procurement is driven by patient needs, leading to regular, moderate-sized orders aligned with treatment schedules.
- Re-exporters: Companies like TILLOMED MALTA LTD (Malta) and TILLOMED ITALIA SRL (Italy) may act as re-exporters, importing Carmustine for redistribution to other markets. This segment's buying behavior includes purchasing in bulk and managing logistics to serve multiple regions.
- Contract Manufacturers: Entities such as AVET PHARMACEUTICALS INC. (United States) and EVERSANA LIFE SCIENCES SERVICES, LLC (United States) may import Carmustine as raw material for further processing or formulation. Their procurement patterns involve bulk purchases aligned with production schedules and regulatory compliance requirements.
Understanding these segments is crucial for tailoring supply strategies and ensuring efficient distribution of Carmustine across diverse markets.
Country-Specific Import Regulations
TransData Nexus Carmustine buyer market intelligence
1Country-Specific Import Regulations
Import regulations for Carmustine vary across the top importing countries:
- United Kingdom:
- Regulatory Authority: Medicines and Healthcare products Regulatory Agency (MHRA).
- Import Registration Process: Importers must hold a Wholesale Dealer's Licence (WDA(H)) and ensure that Carmustine is registered under the UK Marketing Authorisation.
- Estimated Timeline for Registration: Approximately 6-12 months, depending on the completeness of the application and MHRA's review process.
- Import Tariff/Duty for HS 30049049: Pharmaceutical products under this HS code are typically subject to a 0% import duty in the UK.
- Canada:
- Regulatory Authority: Health Canada.
- Import Registration Process: Importers must obtain a Drug Establishment Licence (DEL) and ensure Carmustine is listed on the Notice of Compliance (NOC) database.
- Estimated Timeline for Registration: Approximately 12-18 months, contingent on the submission's complexity and Health Canada's evaluation.
- Import Tariff/Duty for HS 30049049: Pharmaceuticals under this code are generally duty-free in Canada.
- Malta:
- Regulatory Authority: Malta Medicines Authority (MMA).
- Import Registration Process: Importers need a Wholesale Dealer Licence and must ensure Carmustine is authorized for the Maltese market.
- Estimated Timeline for Registration: Approximately 6-9 months, subject to MMA's assessment procedures.
- Import Tariff/Duty for HS 30049049: As an EU member, Malta applies a 0% import duty on pharmaceutical products under this HS code.
- United States:
- Regulatory Authority: U.S. Food and Drug Administration (FDA).
- Import Registration Process: Importers must register with the FDA, and Carmustine must have an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA).
- Estimated Timeline for Registration: Approximately 12-24 months, depending on the application type and FDA's review process.
- Import Tariff/Duty for HS 30049049: Pharmaceuticals under this code are typically duty-free in the U.S.
- Lithuania:
- Regulatory Authority: State Medicines Control Agency (SMCA).
- Import Registration Process: Importers must obtain a Wholesale Distribution Authorisation and ensure Carmustine is registered in Lithuania.
- Estimated Timeline for Registration: Approximately 6-12 months, based on SMCA's evaluation process.
- Import Tariff/Duty for HS 30049049: As an EU member, Lithuania applies a 0% import duty on pharmaceutical products under this HS code.
Compliance with these regulations is essential for market entry and sustained distribution of Carmustine in these countries.
Demand Drivers & Market Opportunity
TransData Nexus Carmustine buyer market intelligence
1Demand Drivers & Market Opportunity
The demand for Carmustine in importing countries is influenced by several factors:
- Disease Prevalence: Carmustine is primarily used in the treatment of certain cancers, including brain tumors and Hodgkin's lymphoma. The global incidence of these cancers has been rising, necessitating increased availability of effective treatments.
- Government Healthcare Programs: Many countries have national cancer control programs that prioritize access to essential oncology drugs. For instance, the WHO's inclusion of new cancer treatments in its Essential Medicines List in 2025 underscores the global commitment to improving cancer care.
- Universal Health Coverage Expansion: Efforts to achieve universal health coverage have led to increased procurement of essential medicines, including Carmustine, to ensure comprehensive cancer treatment is accessible to all patients.
- WHO Essential Medicines List Procurement: The inclusion of Carmustine in the WHO Essential Medicines List facilitates its procurement by member countries, aligning with international standards for essential cancer treatments.
- Tender-Based Purchasing: Many healthcare systems utilize tender processes to procure pharmaceuticals, ensuring cost-effectiveness and consistent supply. The presence of 135 buyers across 54 countries indicates a competitive market where tendering is a common practice.
These factors collectively drive the demand for Carmustine, presenting significant market opportunities for suppliers to meet the growing needs of global healthcare systems.
Official References & Regulatory Resources
- European Medicines Agency
- WHO Essential Medicines
- Invest India — Pharma Sector
- India Trade Statistics (DGFT)
Verify import regulations and drug registration requirements with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Buyer Identification: 135 global importers of Carmustine identified from consignee fields in DGFT shipping bill records.
- 2.Import Value Analysis: Total import value aggregated from 340 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Geographic Distribution: Buyer imports distributed across 54 destination countries with market share per buyer calculated from capped values.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
340 Verified Shipments
135 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists